Evidence map›Paper›PMID 30012200›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop.

Feifei Zhang, Kaitao Li, Mingxin Pan, Weidong Li, Juan Wu, Mingyi Li, Liang Zhao, Hui Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Leukaemia inhibitory factor in gastric cancer: friend or foe?Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Review
  17. Frontiers in oncology · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Feifei ZhangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kaitao LiDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mingxin PanSecond Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Weidong LiDepartment of Medical Oncology, Affiliated Cancer Hospital & Institutes of Guangzhou Medical University, Guangzhou, China.
Juan WuDepartment of Medical Oncology, Affiliated Cancer Hospital & Institutes of Guangzhou Medical University, Guangzhou, China.
Mingyi LiRadiotherapy Department, Affiliated Cancer Hospital & Institues of Guangzhou Medical University, Guangzhou, China.
Liang ZhaoDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China. liangsmu@foxmail.com.
Hui WangDepartment of Medical Oncology, Affiliated Cancer Hospital & Institutes of Guangzhou Medical University, Guangzhou, China. wanghui_0226@126.com.
Guangzhou Medical University · CNSouthern Medical University · CNZhujiang Hospital · CN

Funding

Guangdong Natural Science Foundation 2015A030313274Higher Education Fund Project of Guangzhou 2012C070National Natural Science Foundation of China Nos. 81773082National Natural Science Foundation of China (CN) Nos. 81572813Science and Technology Program of Guangzhou 1563000235Zhujiang Star 2015 of Science and Technology Program of Gugangzhou 201506010037
6 · The paper itself

Abstract

backgroundAs novel biomarkers for various cancers, microRNAs negatively regulate genes expression via promoting mRNA degradation and suppressing mRNA translation. miR-589 has been reported to be deregulated in several human cancer types. However, its biological role has not been functionally characterized in gastric cancer. Here, we aim to investigate the biological effect of miR-589 on gastric cancer and to reveal the possible mechanism.

methodsReal-time PCR was performed to evaluate the expression of miR-589 in 34 paired normal and stomach tumor specimens, as well as gastric cell lines. Functional assays, such as wound healing, transwell assays and in vivo assays, were used to detect the biological effect of miR-589 and LIFR. We determined the role of miR-589 in gastric cancer tumorigenesis in vivo using xenograft nude models. Dual-luciferase report assays and Chromatin immunoprecipitation (ChIP) assay were performed for target evaluation, and the relationships were confirmed by western blot assay.

resultMiR-589 expression was significantly higher in tumor tissues and gastric cancer cells than those in matched normal tissues and gastric epithelial cells, respectively. Clinically, overexpression of miR-589 is associated with tumor metastasis, invasion and poor prognosis of GC patients. Gain- and loss-of function experiments showed that miR-589 promoted cell migration, metastasis and invasion in vitro and lung metastasis in vivo. Mechanistically, we found that miR-589 directly targeted LIFR to activate PI3K/AKT/c-Jun signaling. Meanwhile, c-Jun bound to the promoter region of miR-589 and activated its transcription. Thus miR-589 regulated its expression in a feedback loop that promoted cell migration, metastasis and invasion.

conclusionOur study identified miR-589, as an oncogene, markedly induced cell metastasis and invasion via an atypical miR-589-LIFR-PI3K/AKT-c-Jun feedback loop, which suggested miR-589 as a potential biomarker and/or therapeutic target for the gastric cancer management.

Indexed as

AnimalsCell Line, TumorFemaleHumansMaleMiceMice, NudeMicroRNAsNeoplasm MetastasisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktStomach NeoplasmsMicroRNAsMIRN589 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktFeedback loopGastric cancerLIFRMetastasismiR-589

Identifiers

PMID30012200
PMCPMC6048856
OpenAlexW2884482057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.